ARTICLE | Financial News
Xanodyne raises $38M, names Valentino CEO
June 5, 2009 2:35 AM UTC
Xanodyne Pharmaceuticals Inc. (Newport, Ky.) raised $38 million in a private round led by MPM Capital. AIG Investments; Aisling Capital; Blue Chip Venture; Essex Woodlands; HealthCare Ventures; and Union Springs also participated. All are existing investors.
Xanodyne also named Michael Valentino, a director, as president and CEO. Previously, he was president and CEO of Adams Respiratory Therapeutics Inc., which was acquired last year by Reckitt Benckiser plc (LSE:RB). ...